The beneficial effect of beta-blockers on the treatment of patients with essential hypertension (EH) has been demonstrated,but there is evidence of differential effects among them. We assess the effects of Talliton (Carvedilol) on coronary flow reserve (CFR) in patients with EH.
P-117 2-ARACHIDONYLGLYCEROL AND ITS METABOLITE, GLYCERATED EPOXYEICOSATRIENOIC ACID MEDIATE CA 2؉ -INDUCED RELAXATION OF ISOLATED MESENTERIC ART
We have previously showed that Ca 2ϩ -induced relaxation of pre-contracted mesenteric arteries is blocked by the K Ca channel blockers, iberiotoxin and charybdotoxin as well as the cannabinoid receptor antagonists, SR141716 and O-1918, suggesting a role for a hyperpolarizing vasodilator with activity at an endocannabinoid receptor. In the present study we demonstrate that Ca 2ϩ -induced relaxation of isolated arteries, pre-contracted with phenylepherine, was reversibly blocked by the diacylglycerol (DAG) lipase (DAGL) inhibitor, RCH 80267 (IC 50 ϭ 2.8 Ϯ 0.4 vs 1.4 Ϯ 0.3 mM, control; n ϭ 4) and by cytochrome P450 epoxygenase inhibitors, miconazole (complete) and quinacrine (partially; IC 50 ϭ 4.9 Ϯ 0.4 vs. 2.0 Ϯ 0.3 mM, control; n ϭ 3) indicating involvement of metabolites of this pathway (Figure 1 ). The data suggest that DAG was metabolized to 2-arachidonyl glycerol (2-AG), an endocannabinoid, and subsequently to glycerated epoxyeicosatrienoic acid (GEET). We next determined whether either or both of these metabolites cause relaxation of mesenteric arteries.
Synthetic 2-AG and 14,15-GEET induced dose-dependent relaxation of isolated arteries, which, in the latter case was blocked by iberiotoxin. The findings indicate that 2-AG and GEET play a role in Ca 2ϩ -induced relaxation of resistance arteries. Therefore this pathway is potential target for development of new anti-hypertensive therapy. The purpose of the study was to compare the antihypertensive efficacy of irbesartan 150 mg vs. valsartan 80 mg, when combined with hydrochlorothiazide (HCTZ) 12.5 mg. Untreated or uncontrolled treated hypertensive adults (nϭ800) were enrolled (V1) in a 5-week open-label lead-in phase in which they received 12.5 mg HCTZ od. Those whose blood pressure remained uncontrolled (office SBP Ͼ 140 mm Hg after 4 weeks (V2) and SBP Ͼ 135 mm Hg by home blood pressure monitoring [HBPM] at week 5 -at least 12 valid measurements over 5 days) were randomised (nϭ464) at V3 to either irbesartan/ HCTZ (150/12.5 mg) or valsartan/HCTZ (80/12.5 mg) for 8 weeks.
HBPM was performed at weeks 5 (before V3) and 13 (before V4) using a validated device (Tensioday®): after 5 minutes rest, 3 measurements were made at 1 minute intervals, in a sitting position in the morning (6-10 am) before treatment intake and in the evening (6-10 pm), for at least 3 days. Data were transferred automatically via teletransmission to an independent core laboratory blinded to treatment allocation.
The intent-to-treat dataset included 449 patients (irbesartan/HCTZ: 222 and valsartan/ HCTZ: 227). Baseline characteristics were well matched: mean age 59.3, 56% men; initial home SBP/DBP 148.8/89.5 mm Hg and office SBP/DBP 153.0/90.6 mm Hg. The differences in BP (mm Hg) measured by HBPM (W5-W13) in the morning and in the evening are presented in the 
